Dr Jaymi Lad presents an overview of topical tyrosinase inhibitors and topical adjuncts for hyperpigmentation treatment
Hyperpigmentation encompasses a heterogeneous group of acquired and inherited pigmentary disorders characterised by excess melanin production, abnormal melanin distribution or impaired melanin transfer.¹ It is one of the most common reasons for dermatology and aesthetic consultations, particularly among patients with darker Fitzpatrick skin phototypes, where it can have a significant psychosocial impact.¹˒²
Topical therapy, combined with photoprotection, remains the first-line treatment for predominantly epidermal hyperpigmentation and may also be used to prime the skin before procedural treatments, reducing the risk of post-inflammatory hyperpigmentation (PIH) in susceptible patients.¹˒³˒⁴
Clinical examination plays a key role in establishing the diagnosis by identifying the pattern and distribution of pigmentation, the anatomical sites affected which can include sun-exposed areas such…
